Response to “Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped” - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole
Authors:
- 29 April 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 102 (2) , 190
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be GenotypedClinical Pharmacology & Therapeutics, 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapyClinical Pharmacology & Therapeutics, 2016
- A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?International Journal of Antimicrobial Agents, 2016
- Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazoleEuropean Journal of Clinical Microbiology & Infectious Diseases, 2014
- Inflammation Is Associated with Voriconazole Trough ConcentrationsAntimicrobial Agents and Chemotherapy, 2014
- Pharmacogenomics of the Triazole Antifungal Agent VoriconazolePharmacogenomics, 2011
- Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomesBiochemical Pharmacology, 2007